Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 11/20 | 0.53 |
| ▸ | CCNH | P51946 | 6/20 | 0.53 |
| ▸ | MNAT1 | P51948 | 6/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.53 |
| ▸ | CDK9 | P50750 | 6/20 | 0.53 |
| ▸ | CDK2 | P24941 | 8/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.53 |
| ▸ | CCNK | O75909 | 3/20 | 0.47 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 8/20 | 0.46 |
| ▸ | JUN | P05412 | 7/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19580260 | 1.00 | CDK7 (0.53) | CDK7CCNHMNAT1CCNT1CDK9 | |
| SCHEMBL19024464 | 0.89 | CDK7 (0.48) | CDK7CCNHMNAT1CCNT1CDK9 | |
| SCHEMBL17688369 | 0.88 | CDK7 (0.49) | CDK7CCNHMNAT1CCNT1CDK9 | |
| SCHEMBL19605646 | 0.88 | CDK7 (0.56) | CDK7CCNHMNAT1CCNT1CDK9 | |
| SCHEMBL20412349 | 0.88 | CDK7 (0.48) | CDK7CCNHMNAT1CCNT1CDK9 | |
| SCHEMBL17696392 | 0.88 | CDK7 (0.70) | CDK7CCNHMNAT1CCNT1CDK9 | |
| SCHEMBL20412351 | 0.87 | CDK7 (0.49) | CDK7CCNHMNAT1CCNT1CDK9 | |
| SCHEMBL17696259 | 0.87 | CDK7 (0.59) | CDK7CCNHMNAT1CCNT1CDK9 | |
| SCHEMBL16654985 | 0.86 | CDK7 (0.52) | CDK7CCNHMNAT1CCNT1CDK9 | |
| SCHEMBL16654987 | 0.86 | CDK7 (0.52) | CDK7CCNHMNAT1CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20190337940-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-11-07 | — | — | US | disclosed |
| US-10308648-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337940-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 32/4885MNAT1 106/4885 |
| US-10308648-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 32/4885MNAT1 106/4885 |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 32/4885MNAT1 106/4885 |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 32/4885MNAT1 106/4885 |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 32/4885MNAT1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.